Medindia

X

Tekia Enters Into Distribution Agreement With Fritz Ruck/T-MED, Germany to Market Its Accommodative Intraocular Lens to Treat Presbyopia

Friday, May 21, 2010 General News J E 4
Advertisement

IRVINE, Calif., May 20 /PRNewswire/ -- Tekia, Inc., an ophthalmic medical device company, announced today it has entered into an exclusive distribution agreement, for Germany, with Fritz Ruck/T-MED of Baesweiler, Germany to market its Tek-Clear Accommodative Intraocular Lens used in the treatment of presbyopia, an eye disorder that affects near vision in middle age and older people worldwide. Fritz Ruck/T-MED is launching the Tek-Clear Accommodative Lens at the upcoming World Ophthalmology Congress (WOC) in Berlin during the second week of June 2010.

"This advanced lens design is implanted into the eye during cataract surgery and utilizes the eye's ocular structures to enable the lens to move and change shape therefore allowing the patient to see near, intermediate and distant objects," stated Gene Currie, Tekia's President & CEO. He also stated, "This lens is used in earlier cataract patients with presbyopia to restore vision and eliminate or minimize the need to wear corrective glasses or contact lens."  

Tekia is an ophthalmic medical device company which designs, develops, manufactures and markets a complete line of intraocular lenses to treat cataract, presbyopia and myopia.  The company currently sells its Tek-Clear Accommodative lens in Europe and Latin America and is completing the registration processes in several countries throughout the world.

The company has various lens designs under development to provide patients with higher visual satisfaction. The company has also been issued patents to protect its Tek-Clear Accommodative lens and other lens designs.

www.tekia.com

SOURCE Tekia, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Jennerex Reports Positive Phase 1 Results for JX-5...
S
Venter Institute Scientists, Along with Consortium...